Interestingly, treatment of an AQP4 NMO patient with tocilizumab led to reduction in the frequency of CD19int CD27hi CD38hi SLPBs and anti-AQP4 antibody titer within one month of treatment (274). This evidence concerns the gene AQP4 and neuromyelitis optica.